GCM
BLPH

Gables Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Gables Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-93
Closed -$1K – 370
2019
Q2 		$1K Hold
93
– – ﹤0.01% 330
2019
Q1 		$1K Hold
93
– – ﹤0.01% 341
2018
Q4 		$1K Hold
93
– – ﹤0.01% 362
2018
Q3 		$2K Hold
93
– – ﹤0.01% 364
2018
Q2 		$3K Buy
+93
New +$3.22K ﹤0.01% 357

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gables Capital Management's BLPH Position: Q3 2019 in Review

Gables Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2019, closing a stake of 93 shares — an estimated $1K sold.

Gables Capital Management first reported a position in BLPH in Q2 2018 and held it in 5 quarters. The position peaked at $3K in Q2 2018. 23 funds tracked by Wall St. Rank hold BLPH as of Q3 2019.

  • Gables Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Gables Capital Management sold 93 Bellerophon Therapeutics, Inc. shares in Q3 2019, an estimated $1K.
  • Gables Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q2 2018 and held it in 5 quarters.
  • Gables Capital Management's Bellerophon Therapeutics, Inc. position peaked at $3K in Q2 2018.
  • 23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2019.

Based on Gables Capital Management's 13F filing for Q3 2019, filed 30 Oct 2019.